JP2009511568A5 - - Google Patents

Download PDF

Info

Publication number
JP2009511568A5
JP2009511568A5 JP2008535136A JP2008535136A JP2009511568A5 JP 2009511568 A5 JP2009511568 A5 JP 2009511568A5 JP 2008535136 A JP2008535136 A JP 2008535136A JP 2008535136 A JP2008535136 A JP 2008535136A JP 2009511568 A5 JP2009511568 A5 JP 2009511568A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
compound
composition according
formula
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008535136A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009511568A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2006/004181 external-priority patent/WO2007119108A2/en
Publication of JP2009511568A publication Critical patent/JP2009511568A/ja
Publication of JP2009511568A5 publication Critical patent/JP2009511568A5/ja
Withdrawn legal-status Critical Current

Links

JP2008535136A 2005-10-13 2006-10-13 イノシトール誘導体、ならびに異常なタンパク質の折りたたみまたは凝集、あるいはアミロイドの形成、沈着、蓄積または残存を特徴とする疾患の処置におけるその使用 Withdrawn JP2009511568A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72563405P 2005-10-13 2005-10-13
PCT/IB2006/004181 WO2007119108A2 (en) 2005-10-13 2006-10-13 Inositol derivatives and their uses in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, deposition, accumulation or persistence

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012235331A Division JP2013018791A (ja) 2005-10-13 2012-10-25 イノシトール誘導体、ならびに異常なタンパク質の折りたたみまたは凝集、あるいはアミロイドの形成、沈着、蓄積または残存を特徴とする疾患の処置におけるその使用

Publications (2)

Publication Number Publication Date
JP2009511568A JP2009511568A (ja) 2009-03-19
JP2009511568A5 true JP2009511568A5 (enExample) 2009-11-26

Family

ID=37942269

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008535136A Withdrawn JP2009511568A (ja) 2005-10-13 2006-10-13 イノシトール誘導体、ならびに異常なタンパク質の折りたたみまたは凝集、あるいはアミロイドの形成、沈着、蓄積または残存を特徴とする疾患の処置におけるその使用
JP2012235331A Pending JP2013018791A (ja) 2005-10-13 2012-10-25 イノシトール誘導体、ならびに異常なタンパク質の折りたたみまたは凝集、あるいはアミロイドの形成、沈着、蓄積または残存を特徴とする疾患の処置におけるその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012235331A Pending JP2013018791A (ja) 2005-10-13 2012-10-25 イノシトール誘導体、ならびに異常なタンパク質の折りたたみまたは凝集、あるいはアミロイドの形成、沈着、蓄積または残存を特徴とする疾患の処置におけるその使用

Country Status (5)

Country Link
US (4) US20070111970A1 (enExample)
EP (1) EP1940373B8 (enExample)
JP (2) JP2009511568A (enExample)
CA (1) CA2626005A1 (enExample)
WO (2) WO2007041855A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
US9017724B2 (en) 2004-02-24 2015-04-28 The General Hospital Corporation Catalytic radiofluorination
US8257680B1 (en) 2004-02-24 2012-09-04 The General Hospital Corporation Catalytic radiofluorination
JP2009511568A (ja) * 2005-10-13 2009-03-19 ワラタ ファーマシューティカルズ， インコーポレイテッド イノシトール誘導体、ならびに異常なタンパク質の折りたたみまたは凝集、あるいはアミロイドの形成、沈着、蓄積または残存を特徴とする疾患の処置におけるその使用
WO2008034244A1 (en) * 2006-09-21 2008-03-27 Waratah Pharmaceuticals Inc. The combination of a cyclohexanehexol and a nsaid for the treatment of neurodegenerative diseases
EP2091566A4 (en) * 2006-11-24 2011-07-06 Waratah Pharmaceuticals Inc COMBINATION THERAPIES AGAINST ALZHEIMER DISEASE AND SIMILAR ILLNESSES
AU2013248197B2 (en) * 2008-03-21 2016-05-12 The General Hospital Corporation Compounds and compositions for the detection and treatment of Alzheimer's disease and related disorders
EP3231804B1 (en) * 2008-03-21 2021-03-03 The General Hospital Corporation Compounds and compositions for the detection and treatment of alzheimer's disease and related disorders
KR101021078B1 (ko) * 2008-07-22 2011-03-14 포항공과대학교 산학협력단 이노시톨 또는 트리할로스 유도체 및 이를 함유하는 퇴행성뇌신경계 질환 치료용 약학 조성물
EP2313363A4 (en) 2008-08-08 2014-04-02 Univ Florida Lipid compounds for supression of tumorigenesis
US20100279997A1 (en) * 2009-05-04 2010-11-04 Lindsay Burns Barbier Analgesic that binds filamin a
GB0920985D0 (en) * 2009-11-30 2010-01-13 Queen Mary & Westfield College Novel inositol phosphate derivatives
US8394858B2 (en) 2009-12-03 2013-03-12 Novartis Ag Cyclohexane derivatives and uses thereof
EA201290801A1 (ru) * 2010-02-15 2013-03-29 Эббви Инк. Способ получения сциллоинозита
EP2390245A1 (en) * 2010-05-26 2011-11-30 Nabriva Therapeutics AG Enantiomerically pure amines
US9320793B2 (en) * 2010-07-14 2016-04-26 Acumen Pharmaceuticals, Inc. Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
CN103402954A (zh) 2010-10-13 2013-11-20 依兰制药公司 鲨肌醇和相关化合物的合成方法
FR2989088B1 (fr) * 2012-04-04 2014-08-29 Univ Lorraine Radiotraceur pour la maladie d'alzheimer
WO2014012054A1 (en) 2012-07-13 2014-01-16 Pain Therapeutics, Inc. Alzheimer's disease assay in a living patent
GB201312499D0 (en) * 2013-07-12 2013-08-28 Isis Innovation Therapeutic compounds
GB201416017D0 (en) 2014-09-10 2014-10-22 New Royal Holloway & Bedford An Anticonvulsant Compound
US9744251B2 (en) 2014-10-08 2017-08-29 Texas Children's Hospital MRI imaging of amyloid plaque using liposomes
US11247970B2 (en) 2017-03-22 2022-02-15 Dana-Farber Cancer Institute, Inc. Selective inhibition of gluconeogenic activity
US12352719B2 (en) 2019-09-20 2025-07-08 KYCERA AVX Components Corporation Somatic cell-based electrical biosensor
KR102816558B1 (ko) 2019-11-05 2025-06-05 아주대학교산학협력단 종양 괴사 인자 알파(TNF-α) 소분자 억제제
JP7338918B1 (ja) 2022-10-21 2023-09-05 築野食品工業株式会社 イノシトール脂肪酸エステル

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4454151A (en) * 1982-03-22 1984-06-12 Syntex (U.S.A.) Inc. Use of pyrrolo pyrroles in treatment of ophthalmic diseases
US4515722A (en) * 1982-03-30 1985-05-07 Merck & Co., Inc. Phosphatidyl inositol analogs useful as anti-inflammatory/analgesic agents
US4474806A (en) * 1982-05-10 1984-10-02 Merck & Co., Inc. Sulfonyl or carbonyl inositol derivatives useful as anti-inflammatory/analgesic agents
US4952396A (en) * 1986-11-19 1990-08-28 Linus Pauling Institute Of Science & Medicine Method of using phytic acid for inhibiting tumor growth
US4758430A (en) * 1987-01-21 1988-07-19 Robert Sabin Method of treatment of Alzheimer's disease using phytic acid
US4847082A (en) * 1987-01-21 1989-07-11 Robert Sabin Method of treatment of Alzheimer's disease using phytic acid
SE8904355D0 (sv) * 1989-12-21 1989-12-21 Perstorp Ab Medicament
US5217959A (en) * 1990-09-06 1993-06-08 Robert Sabin Method of treating multiple sclerosis with phytic acid
US5112814A (en) * 1990-10-24 1992-05-12 Robert Sabin Method of treatment of Parkinson's disease using phytic acid
KR0185215B1 (ko) * 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
SE9102068L (sv) * 1991-07-03 1993-01-04 Perstorp Ab Derivat av inositol, kompositioner innehaallande dessa samt anvaendning daerav
SE9200547L (sv) * 1992-02-25 1993-06-14 Perstorp Ab En farmaceutisk komposition med foerbaettrad biotillgaenglighet avseende inositolfosfat
DE69332542T2 (de) * 1992-10-05 2003-08-14 Virginia Tech Intellectual Properties Inc., Blacksburg Synthesen von d-chiro-3-inosose und (+)-d-chiro-inositol
US5972328A (en) * 1993-03-29 1999-10-26 Queen's University At Kingston Method for treating amyloidosis
US5643562A (en) * 1993-03-29 1997-07-01 Queen's University Of Kingston Method for treating amyloidosis
US5840294A (en) * 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
DK0619369T3 (da) * 1993-04-05 2003-10-06 Aveve Nv Phytathydrolyse og enzymsammensætning til hydrolyse af phytat
ES2130440T3 (es) * 1993-08-11 1999-07-01 Hokko Chem Ind Co Proceso para producir d-(quiro)-inositol.
SE502574C2 (sv) * 1994-01-25 1995-11-13 Perstorp Ab En farmaceutisk komposition med förbättrad biotillgänglighet hos inositolfosfat
US5550166A (en) * 1995-03-17 1996-08-27 Ostlund; Richard E. Pinitol and derivatives thereof for the treatment of metabolic disorders
US5858326A (en) * 1995-06-06 1999-01-12 Neurochem, Inc. Methods of increasing amyloid deposition
US5756541A (en) * 1996-03-11 1998-05-26 Qlt Phototherapeutics Inc Vision through photodynamic therapy of the eye
US6232486B1 (en) * 1996-06-11 2001-05-15 Nutrimed Biotech Molecular probes and modulators for PI-PLC and PI 3-kinase
US5977078A (en) * 1996-09-20 1999-11-02 The Regents Of The Univesity Of California Inositol polyphosphate derivatives and methods of using same
US5880099A (en) * 1996-09-20 1999-03-09 The Regents Of The University Of California Inositol polyphosphates and methods of using same
US5998485A (en) * 1997-06-16 1999-12-07 Cedars-Sinai Medical Center Method for modulating immune response with inositol
US6153603A (en) * 1997-06-27 2000-11-28 Perstorp Ab Method of treating angiogenesis in tumor tissue
US6310073B1 (en) * 1998-07-28 2001-10-30 Queen's University At Kingston Methods and compositions to treat glycosaminoglycan-associated molecular interactions
US6818430B1 (en) * 1999-06-07 2004-11-16 Hokko Chemical Industry Co., Ltd. Process for producing L-epi-2-inosose and novel process for producing epi-inositol
US6329256B1 (en) * 1999-09-24 2001-12-11 Advanced Micro Devices, Inc. Self-aligned damascene gate formation with low gate resistance
RU2002111408A (ru) * 1999-10-18 2004-05-20 Мусклетеч Ресеч Энд Девелопмент Инк. (Ca) Пищевая добавка для увеличения мышечной массы и силы
US6331313B1 (en) * 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
DE10031955A1 (de) * 2000-06-30 2002-01-17 Deutsches Krebsforsch Curcumin-Derivate mit gegenüber Curcumin verbesserter Wasserlöslichkeit und diese enthaltende Arzneimittel
US7060695B2 (en) * 2001-02-06 2006-06-13 Qlt, Inc. Method to prevent vision loss
EP1357912B9 (en) * 2001-02-06 2012-06-13 QLT Inc. Photodynamic therapy of occult choroidal neovascularization linked to age-related macular degeneration
US20030181531A1 (en) * 2003-02-11 2003-09-25 David Sherris Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
WO2003007944A1 (en) * 2001-07-20 2003-01-30 Qlt, Inc. Treatment of macular edema with photodynamic therapy
US20040058313A1 (en) * 2002-04-24 2004-03-25 Abreu Marcio Marc Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
US6723755B2 (en) * 2002-06-12 2004-04-20 Piotr Chomczynski Method of treating rosacea
AU2002344514A1 (en) * 2002-10-17 2004-05-25 Jingyu Liang A natural compound useful for treating diabetes, its preparation and use
US7521481B2 (en) * 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
KR101314079B1 (ko) * 2003-10-14 2013-10-04 혹꼬우 가가꾸 고오교오 가부시끼가이샤 실로-이노시톨의 제조방법
EP1824496A4 (en) * 2004-11-17 2008-07-16 Joanne Mclaurin COMPOSITIONS OF SCYLLO-INOSITOL DERIVATIVES AND METHOD FOR THE TREATMENT OF PROTEIN AGGREGATION DISORDERS
CA2488034C (en) * 2004-11-19 2009-10-06 Apotex Inc. Process for the manufacture of 3-hydroxy-n-alkyl-1-cycloalkyl-6-alkyl-4-oxo-1,4-dihydropyridine-2-carboxamide and its related analogues
JP2009511568A (ja) * 2005-10-13 2009-03-19 ワラタ ファーマシューティカルズ， インコーポレイテッド イノシトール誘導体、ならびに異常なタンパク質の折りたたみまたは凝集、あるいはアミロイドの形成、沈着、蓄積または残存を特徴とする疾患の処置におけるその使用
CA2652449A1 (en) * 2006-05-19 2007-11-29 Waratah Pharmaceuticals Inc. Screening methods for amyloid beta modulators

Similar Documents

Publication Publication Date Title
JP2009511568A5 (enExample)
RU2470016C2 (ru) Производное бипиразола
JP2006523216A5 (enExample)
JP2018518537A5 (enExample)
MX2009005279A (es) Derivados de n-(metil)-1h-pirazol-3-amina, n-(metil)-piridin-2-ami na y n-(metil)-tiazol-2-amina para el tratamiento de enfermedades asociadas con proteinas amiloides o tipo amiloide, tal como por ejemplo alzheimer.
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
JP2009538327A5 (enExample)
JP2008539268A5 (enExample)
JP2006182786A5 (enExample)
JP2004522714A5 (enExample)
JP2016534063A5 (enExample)
JP2008513510A5 (enExample)
EA201071006A1 (ru) Набор, композиция, продукт или лекарственное средство для лечения нарушения познавательной способности
JP2016522254A5 (enExample)
JP2019533660A5 (enExample)
KR20230107568A (ko) 섬유증 치료 방법
JP2009511450A5 (enExample)
JP2016537432A5 (enExample)
EP2231148A4 (en) Pharmaceutical composition for the treatment and prevention of heart disease
JP2013536206A5 (enExample)
NO20054180D0 (no) Behandling av bakterielle sykdommer i andedrettsorganene ved lokal tilforsel av fluorkinoloner
JP2008500378A5 (enExample)
JP2018525447A5 (enExample)
RU2011111117A (ru) Лечение аутоиммунных заболеваний
RU2006131553A (ru) Комбинация(а) ингибитора топоизомеразы днк и (б) ингибитора iap